CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
REVENUES:
Total revenues	$ 429,485	$ 387,763	$ 931,554	$ 788,508
OPERATING EXPENSES:
Cost of sales	97,967	77,436	209,341	166,618
Research and development	182,139	185,641	324,396	369,232
Selling, general and administrative	175,412	160,754	362,707	322,912
Intangible asset amortization and contingent consideration	14,912	20,286	30,589	40,051
Gain on sale of nonfinancial assets	0	(15,000)	(59,495)	(15,000)
Total operating expenses	470,430	429,117	867,538	883,813
INCOME (LOSS) FROM OPERATIONS	(40,945)	(41,354)	64,016	(95,305)
Equity in the loss of BioMarin/Genzyme LLC	(79)	(44)	(156)	(229)
Interest income	4,291	5,899	9,535	12,197
Interest expense	(8,048)	(6,866)	(14,963)	(13,593)
Other income, net	2,508	470	647	2,078
INCOME (LOSS) BEFORE INCOME TAXES	(42,273)	(41,895)	59,079	(94,852)
Provision for (benefit from) income taxes	(13,090)	(4,460)	6,881	(944)
NET INCOME (LOSS)	$ (29,183)	$ (37,435)	$ 52,198	$ (93,908)
NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share)	$ (0.16)	$ (0.21)	$ 0.29	$ (0.53)
NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share)	$ (0.16)	$ (0.21)	$ 0.28	$ (0.53)
Weighted average common shares outstanding, basic (in shares)	180,729	179,048	180,314	178,662
Weighted average common shares outstanding, diluted (in shares)	180,729	179,048	184,344	178,662
COMPREHENSIVE INCOME (LOSS)	$ (33,260)	$ (39,790)	$ 62,084	$ (81,740)
Net product revenues
REVENUES:
Total revenues	419,032	379,075	908,075	773,558
Royalty and other revenues
REVENUES:
Total revenues	$ 10,453	$ 8,688	$ 23,479	$ 14,950